Scholarlink

<p>Mood symptoms make diagnosis harder in children with attention-deficit/hyperactivity disorder (ADHD). Broadband rating scales often fold irritability, sadness, and high activity into general scores, reducing clinical specificity. This study evaluated the Pediatric Behavior Rating Scale (PBRS) by mapping items to DSM-5 mood criteria and testing external discrimination in published clinical data. Four clinicians mapped PBRS items to criteria for disruptive mood dysregulation disorder (DMDD), depressive disorders, and bipolar disorder. These maps were then applied to published PBRS and Children’s Depression Inventory (CDI) data from 80 Egyptian youth with diagnosed ADHD treated with atomoxetine, assessed at baseline, one week, and one month. Irritability and Aggression aligned with DMDD criteria; Affect, Atypicality, and Social Problems aligned with depressive criteria; and Grandiosity and Hyperactivity captured bipolar-related content. In the clinical sample, depression-linked scales showed the largest baseline differences (Hedges’ g up to 0.90; area under the curve [AUC] up to 0.74) and remained elevated in the comorbid group after one month, whereas ADHD-symptom scales (e.g., Hyperactivity, Aggression) converged across groups with treatment. These findings provide preliminary support for the PBRS as a clinically useful, transdiagnostic assessment for distinguishing persistent mood problems from ADHD-related dysregulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the Validity of the Pediatric Behavior Rating Scale for Mood Problems in Children

  • 期刊论文

  • 发表日期：

    2026年4月2日

查看全文
  • John Hite

摘要

Mood symptoms make diagnosis harder in children with attention-deficit/hyperactivity disorder (ADHD). Broadband rating scales often fold irritability, sadness, and high activity into general scores, reducing clinical specificity. This study evaluated the Pediatric Behavior Rating Scale (PBRS) by mapping items to DSM-5 mood criteria and testing external discrimination in published clinical data. Four clinicians mapped PBRS items to criteria for disruptive mood dysregulation disorder (DMDD), depressive disorders, and bipolar disorder. These maps were then applied to published PBRS and Children’s Depression Inventory (CDI) data from 80 Egyptian youth with diagnosed ADHD treated with atomoxetine, assessed at baseline, one week, and one month. Irritability and Aggression aligned with DMDD criteria; Affect, Atypicality, and Social Problems aligned with depressive criteria; and Grandiosity and Hyperactivity captured bipolar-related content. In the clinical sample, depression-linked scales showed the largest baseline differences (Hedges’ g up to 0.90; area under the curve [AUC] up to 0.74) and remained elevated in the comorbid group after one month, whereas ADHD-symptom scales (e.g., Hyperactivity, Aggression) converged across groups with treatment. These findings provide preliminary support for the PBRS as a clinically useful, transdiagnostic assessment for distinguishing persistent mood problems from ADHD-related dysregulation.